Pancreatic cancer genetic epidemiology consortium
Pancreatic cancer genetic epidemiology consortium
复制标题
DOI：
10.1158/1055-9965.epi-05-0734
复制
发表时间：
2006-04-01
影响因子：
3.8
通讯作者：
Kiein, AP
中科院分区：
文献类型：
--
作者：
Petersen, GM;de Andrade, M;Kiein, AP
我们组织了胰腺癌遗传流行病学 (PACGENE) 联盟来识别家族性胰腺癌 (FPC) 的易感基因。该联盟由七个数据收集中心、一个统计遗传学核心和一个病理/档案基因分型核心组成。我们招募包含两个或更多受影响血亲的亲属，这些血亲是通过胰腺腺癌事件病例、医生转介和/或通过互联网招募确定的。包含来自调查问卷的核心临床、人口统计、生活方式和家族史信息的数据库以及生物样本的收集正在进行中。迄今为止，已有 13,147 名患者接受了家族史筛查，其中 476 名先证者（50% 为男性）及其 1,912 名成年亲属（99% 未受影响）已入组。其中，379 个亲属符合 FPC 标准，其中至少有两名一级亲属患有胰腺癌。将使用可用诊断年龄（发病年龄）和受影响亲属的累积发病率曲线与 1973 年至 2000 年期间向 13 个美国流行病学监测和最终结果 (SEER) 站点报告的胰腺癌病例进行比较 (N = 72,700)。 466 名 PACGENE 先证者和 670 名受影响亲属的诊断时平均年龄 +/- SD 为 64.1 +/- 11.8，369 名 FPC 先证者和 429 名亲属的子集为 65.4 +/- 11.6。两个样本均显着低于 SEER 人群诊断时的平均年龄（70.0 +/- 12.1 岁；曲线与 SEER 的差异，P < 0.001）。 FPC 亲属的诊断年龄（不包括先证者）不会随着受影响个体数量的增加而降低。在我们的样本中，无论我们是通过主要通过高风险转诊招募的招募地点对先证者进行分组，还是通过筛查所有胰腺癌患者的家族史，都观察到诊断时的年龄较小。关联研究正在进行中。 PACGENE 联盟将是一个宝贵的基于家庭的资源，将极大地加强胰腺癌的遗传流行病学研究。
We have organized the Pancreatic Cancer Genetic Epidemiology (PACGENE) Consortium to identify susceptibility genes in familial pancreatic cancer (FPC). The Consortium comprises seven data collection centers, a statistical genetics core, and a pathology/archival genotyping core. We recruit kindreds containing two or more affected blood relatives ascertained through incident pancreatic adenocarcinoma cases, physician referrals, and/or through Internet recruitment. Accrual to a database containing core clinical, demographic, lifestyle, and family history information from questionnaires is ongoing, along with biospecimen collection. To date, 13,147 patients have been screened for family history, of whom 476 (50% male) probands and 1,912 of their adult (99% unaffected) relatives have been enrolled. Of these, 379 kindreds meet criteria for FPC, having at least two first-degree relatives with pancreatic cancer. Cumulative incidence curves using available age of diagnosis (onset) among and affected relatives were compared with those for incident pancreatic cancer cases reported to 13 U.S. Surveillance Epidemiology and End Results (SEER) sites from 1973 to 2000 (N = 72,700). The mean age +/- SD at diagnosis among 466 PACGENE probands and 670 affected relatives was 64.1 +/- 11.8 and was 65.4 +/- 11.6 for the subset of 369 FPC probands and 429 relatives. Both samples were significantly younger than the mean age at diagnosis in the SEER population (70.0 +/- 12.1 years; differences in curves versus SEER, P < 0.001). Age at diagnosis (excluding probands) in FPC kindreds does not decrease with increasing number of affected individuals. In our sample, younger age at diagnosis was observed whether we grouped probands by recruitment sites that predominantly recruited through high-risk referrals, or through screening all pancreatic cancer patients for family history. Linkage studies are ongoing. The PACGENE Consortium will be a valuable family-based resource that will greatly enhance genetic epidemiology research in pancreatic cancer.